Actelion To Present At the Bear Stearns 15th Annual Healthcare Conference.
Business Editors
ALLSCHWIL/BASEL, Switzerland--(BUSINESS WIRE)--Sept. 11, 2002
Actelion (SWX Swiss Exchange SWX Swiss Exchange
An all-electronic securities exchange formed from the 1995 merger of exchanges in Geneva, Basel, and Zurich. The exchange offers trading in equity securities, investment funds, exchange-traded funds, bonds, Eurobonds, and options. : ATLN) announced today that it has been invited to present at the Bear Stearns 15th Annual Healthcare Conference from 16:00 to 16:30 EST EST electroshock therapy.
EST
abbr.
electroshock therapy on 17 September 2002. Presenter is Andre J. Mueller, Chief Financial Officer of Actelion.
This presentation is being webcasted by CCBN CCBN Central Coast Bancorp
CCBN Charles County Business Network and can be accessed at Actelion's website at www.actelion.com.
Actelion Ltd
Actelion Ltd is a biopharmaceutical company, with its corporate headquarter in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(TM), an orally available dual endothelin receptor antagonist A endothelin receptor antagonist (ERA) is a drug which blocks endothelin receptors.
Two main kinds of ERAs exist: - selective ERA (e.g. sitaxsentan), which affect endothelin A.
- dual ERAs,(e.g. bosentan) which affect both endothelin A and B .
, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(TM) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. ), the European Union as well as Canada and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Related Articles
| D&K Healthcare to Present On September 17th At Bear, Stearns & Co.'s 15th Annual Healthcare Conference; Presentation and Replay Available to All... | | CuraGen to Post its Bear Stearns 15th Annual Healthcare Conference Presentation at www.curagen.com. | | SICOR, Inc. Presenting At the Bear Stearns 15th Annual Healthcare Conference. | | Triangle Pharmaceuticals, Inc. to Present at the Bear Stearns 15th Annual Healthcare Conference. | | Andrx to Present at Bear Stearns' Healthcare Conference. | | IDEXX Laboratories To Present at Bear Stearns Healthcare Conference. | | Barr Laboratories, Inc. Announces Live Audiocast of Presentation at Bear Stearns 15th Annual Healthcare Conference, Tuesday, September 17, 2002, at... | | ZymoGenetics Announces Webcast of Presentation at Bear Stearns 15th Annual Healthcare Conference. | | SciClone Pharmaceuticals To Present at Bear Stearns' Healthcare Conference Tuesday, September 17, 2002, at 7:00 am ET. | | Curis to Present at the 2005 Bear Stearns Healthcare Conference. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion